个体化与标准血压管理策略对高危大手术患者术后器官功能障碍的影响:一项随机临床试验
INPRESS研究为多中心随机平行组试验,纳入9家法国医院298例术前急性肾损伤风险指数III级及以上、接受全身麻醉下大手术(≥2小时)的成人患者。个体化策略组目标收缩压为参考值(静息收缩压)的10%以内,标准策略组仅在收缩压<80 mmHg或低于参考值40%时处理,干预持续至术后4小时。主要终点(术后7天全身炎症反应综合征合并至少1个器官系统功能障碍)个体化组38.1% vs 标准组51.7%(RR 0.73,95%CI 0.56-0.94,P=0.02;绝对风险差-14%,95%CI -25%至-2%)。术后30天器官功能障碍个体化组46.3% vs 标准组63.4%(校正HR 0.66,95%CI 0.52-0.84,P=0.001)。严重不良事件与30天死亡率组间无显著差异。
要点
- 高危大手术成人患者(术前急性肾损伤风险指数III级及以上),术中及术后4小时个体化收缩压目标(参考值±10%)较标准管理降低术后7天器官功能障碍复合终点(38.1% vs 51.7%,RR 0.73,95%CI 0.56-0.94)。
- 术后30天器官功能障碍个体化组46.3% vs 标准组63.4%,校正HR 0.66(95%CI 0.52-0.84,P=0.001)。
- 标准管理策略为收缩压<80 mmHg或低于参考值40%时处理,个体化策略目标为收缩压控制在参考值(静息收缩压)10%以内。
- 严重不良事件与30天死亡率两组间无显著差异。
- 主要适用于以腹部手术为主的高危患者,结论来自9家法国医院的多中心RCT。
适用人群与场景
- 成人患者(n=298),术前急性肾损伤风险指数III级或更高(提示术后肾损伤中至高危),在全身麻醉下接受持续时间2小时或更长时间的大手术,以腹部手术为主。
- 招募时间2012年12月4日至2016年8月28日,末次随访2016年9月28日。
诊断标准与关键阈值
- 术前急性肾损伤风险指数III级或更高(提示术后肾损伤中至高危)。
- 个体化策略目标:收缩压维持在参考值(患者静息收缩压)10%以内。
- 标准策略处理阈值:收缩压<80 mmHg或低于参考值40%。
处置流程与药物剂量
- 个体化管理策略:术中及术后4小时内,通过调整去甲肾上腺素使收缩压达到参考值(患者静息收缩压)10%以内。
- 标准管理策略:术中及术后4小时内,仅在收缩压<80 mmHg或低于参考值40%时进行治疗。
研究设计与关键结果
- 多中心、随机、平行组临床试验,9家法国大学与非大学医院参与,298例随机,292例完成试验并纳入改良意向治疗分析(平均[SD]年龄70[7]岁;女性44例[15.1%])。
- 主要终点(术后7天全身炎症反应综合征合并肾、呼吸、心血管、凝血、神经系统中至少1个器官系统功能障碍):个体化组56/147例(38.1%)vs 标准组75/145例(51.7%),RR 0.73(95%CI 0.56-0.94),P=0.02;绝对风险差-14%(95%CI -25%至-2%)。
- 术后30天器官功能障碍:个体化组68例(46.3%)vs 标准组92例(63.4%),校正HR 0.66(95%CI 0.52-0.84),P=0.001。
- 严重不良事件与30天全因死亡率两组间无显著差异。
证据类型、等级与局限
- 证据类型:多中心随机平行组临床试验(RCT)。
- 试验注册号:clinicaltrials.gov NCT01536470。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于术前急性肾损伤风险指数III级及以上、接受全身麻醉下大手术(≥2小时)的成人患者,术中及术后4小时以个体化收缩压目标(参考值±10%)管理,较标准管理(收缩压<80 mmHg或低于参考值40%时处理)可降低术后7天器官功能障碍复合终点风险。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Perioperative hypotension is associated with an increase in postoperative morbidity and mortality, but the appropriate management strategy remains uncertain.
OBJECTIVE: To evaluate whether an individualized blood pressure management strategy tailored to individual patient physiology could reduce postoperative organ dysfunction.
DESIGN, SETTING, AND PARTICIPANTS: The Intraoperative Norepinephrine to Control Arterial Pressure (INPRESS) study was a multicenter, randomized, parallel-group clinical trial conducted in 9 French university and nonuniversity hospitals. Adult patients (n = 298) at increased risk of postoperative complications with a preoperative acute kidney injury risk index of class III or higher (indicating moderate to high risk of postoperative kidney injury) undergoing major surgery lasting 2 hours or longer under general anesthesia were enrolled from December 4, 2012, through August 28, 2016 (last follow-up, September 28, 2016).
INTERVENTIONS: Individualized management strategy aimed at achieving a systolic blood pressure (SBP) within 10% of the reference value (ie, patient's resting SBP) or standard management strategy of treating SBP less than 80 mm Hg or lower than 40% from the reference value during and for 4 hours following surgery.
MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of systemic inflammatory response syndrome and dysfunction of at least 1 organ system of the renal, respiratory, cardiovascular, coagulation, and neurologic systems by day 7 after surgery. Secondary outcomes included the individual components of the primary outcome, durations of ICU and hospital stay, adverse events, and all-cause mortality at 30 days after surgery.
RESULTS: Among 298 patients who were randomized, 292 patients completed the trial (mean [SD] age, 70 [7] years; 44 [15.1%] women) and were included in the modified intention-to-treat analysis. The primary outcome event occurred in 56 of 147 patients (38.1%) assigned to the individualized treatment strategy vs 75 of 145 patients (51.7%) assigned to the standard treatment strategy (relative risk, 0.73; 95% CI, 0.56 to 0.94; P = .02; absolute risk difference, -14%, 95% CI, -25% to -2%). Sixty-eight patients (46.3%) in the individualized treatment group and 92 (63.4%) in the standard treatment group had postoperative organ dysfunction by day 30 (adjusted hazard ratio, 0.66; 95% CI, 0.52 to 0.84; P = .001). There were no significant between-group differences in severe adverse events or 30-day mortality.
CONCLUSIONS AND RELEVANCE: Among patients predominantly undergoing abdominal surgery who were at increased postoperative risk, management targeting an individualized systolic blood pressure, compared with standard management, reduced the risk of postoperative organ dysfunction.
TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01536470.
参考来源
- Futier E, Lefrant JY, Guinot PG, et al. Effect of Individualized vs Standard Blood Pressure Management Strategies on Postoperative Organ Dysfunction Among High-Risk Patients Undergoing Major Surgery: A Randomized Clinical Trial. JAMA. 2017. PMID: 28973220. doi:10.1001/jama.2017.14172
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。